Dr Srivastava was selected by an expert jury in recognition of her sustained contributions to renewable chemicals, industrial biotechnology and bioprocess innovation
The acquisition of MDxK further strengthens the Business Unit’s position in the molecular diagnostics market
The companies will spread the adoption of the latest HOS and Mass Spec technologies to help scientists improve the safety, stability, and effectiveness of biotherapeutics
Peak Proteins has collaborated closely with Sygnature Discovery for several years and together the companies have supported a number of integrated drug discovery programmes
It supports advanced research and helps scientists accelerate potential cures, drug discoveries and diagnostics research
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Subscribe To Our Newsletter & Stay Updated
